BioMarin Pharma (BMRN) Tops Q2 EPS by 31c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $57.44 -1.83%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $0.54, $0.31 better than the analyst estimate of $0.23. Revenue for the quarter came in at $595.3 million versus the consensus estimate of $595.22 million.
GUIDANCE:
BioMarin Pharma sees FY2023 EPS of $1.80-$2.05, versus the consensus of $1.02. BioMarin Pharma sees FY2023 revenue of $2.375-2.5 million, versus the consensus of $2.46 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Neurocrine Biosciences (NBIX) Tops Q3 EPS by 138c
- Pampa EnergÃa S.A. (PAM) Misses Q3 EPS by 240c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
